U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H16N2O6S3
Molecular Weight 404.482
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFOXONE

SMILES

OS(=O)CNC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(NCS(O)=O)C=C2

InChI

InChIKey=NEDPPCHNEOMTJV-UHFFFAOYSA-N
InChI=1S/C14H16N2O6S3/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20)

HIDE SMILES / InChI
Molecular Formula C14H16N2O6S3
Molecular Weight 404.482
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Sulfoxone is a water-soluble sulfone and is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. Sulfoxone under the brand name Diasone was used as an antileprosy drug, for treatment of dermatitis herpetiformis, and to treat pulmonary tuberculosis. Presently, usage of diasone has been discontinued.

Approval Year

1947
97
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8146
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8307
DIASONE SODIUM

Approved Use

Unknown

Launch Date

5.11401591E11
Primary
Approved
8307
DIASONE SODIUM

Approved Use

Unknown

Launch Date

5.11401591E11
Primary
Approved
8307
DIASONE SODIUM

Approved Use

Unknown

Launch Date

5.11401591E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
600 ng/mL
REVIEW
https://doi.org/10.1016/S0099-5428(08)60377-9
330 mg single, oral
dose: 330 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DAPSONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Other AEs: Nausea, Weakness...
Other AEs:
Nausea
Weakness
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Other AEs: Malaise...
Other AEs:
Malaise
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Disc. AE: Hemolytic anemia, Methemoglobinemia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia
Methemoglobinemia
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
Disc. AE: Erythema facial, Erythema...
AEs leading to
discontinuation/dose reduction:
Erythema facial
Erythema
Furunculosis
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
AEs

AEs

AESignificanceDosePopulation
Nausea
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Weakness
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Malaise
2.4 g single, oral
Studied dose
Dose: 2.4 g
Route: oral
Route: single
Dose: 2.4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Hemolytic anemia Disc. AE
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Methemoglobinemia Disc. AE
1.2 g 1 times / day multiple, oral
Dose: 1.2 g, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
unhealthy, 50 years
Health Status: unhealthy
Condition: leprosy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/13661194
Erythema facial Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
Erythema Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
Furunculosis Disc. AE
0.3 g 3 times / day multiple, oral
Dose: 0.3 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.3 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
unhealthy, 52 years
n = 1
Health Status: unhealthy
Condition: leprosy
Age Group: 52 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/12996073
Sourcing

Sourcing

Vendor/AggregatorIDURL
AAA Chemistry
AR-1A9274
ABI Chem
AC1L1K5Q
ABI Chem
AC1Q6YP0
BOC Sciences
144-75-2
ChemTik
CTK4C4202
Compound Cloud
5351
Compound Cloud
8954
Kingston Chemistry
KST-1A1474
MuseChem
M069826
NCI Plated 2007
27222
NovoSeek
5351
ZINC
ZINC000018268128
http://zinc15.docking.org/substances/ZINC000018268128
eMolecules
260190822
PubMed

PubMed

TitleDatePubMed
Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS).
2005
Total synthesis of azumamide A and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue.
2007 Mar 15

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 16 19:50:24 UTC 2022
Edited
by admin
on Fri Dec 16 19:50:24 UTC 2022
Record UNII
0G3C18OH4D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFOXONE
Common Name English
METHANESULFINIC ACID, (SULFONYLBIS(4,1-PHENYLENEIMINO))BIS-
Common Name English
Aldesulfone [WHO-DD]
Common Name English
ALDESULFONE
WHO-DD  
Common Name English
(SULFONYLBIS(4,1-PHENYLENEIMINO))DIMETHANESULFINIC ACID
Systematic Name English
ALDESULPHONE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29739
Created by admin on Fri Dec 16 19:50:24 UTC 2022 , Edited by admin on Fri Dec 16 19:50:24 UTC 2022
Code System Code Type Description
WIKIPEDIA
Sulfoxone
Created by admin on Fri Dec 16 19:50:24 UTC 2022 , Edited by admin on Fri Dec 16 19:50:24 UTC 2022
PRIMARY
NCI_THESAURUS
C72856
Created by admin on Fri Dec 16 19:50:24 UTC 2022 , Edited by admin on Fri Dec 16 19:50:24 UTC 2022
PRIMARY
EVMPD
SUB12767MIG
Created by admin on Fri Dec 16 19:50:24 UTC 2022 , Edited by admin on Fri Dec 16 19:50:24 UTC 2022
PRIMARY
FDA UNII
0G3C18OH4D
Created by admin on Fri Dec 16 19:50:24 UTC 2022 , Edited by admin on Fri Dec 16 19:50:24 UTC 2022
PRIMARY
MESH
C036115
Created by admin on Fri Dec 16 19:50:24 UTC 2022 , Edited by admin on Fri Dec 16 19:50:24 UTC 2022
PRIMARY
DRUG CENTRAL
2533
Created by admin on Fri Dec 16 19:50:24 UTC 2022 , Edited by admin on Fri Dec 16 19:50:24 UTC 2022
PRIMARY
CAS
144-76-3
Created by admin on Fri Dec 16 19:50:24 UTC 2022 , Edited by admin on Fri Dec 16 19:50:24 UTC 2022
PRIMARY
DRUG BANK
DB01145
Created by admin on Fri Dec 16 19:50:24 UTC 2022 , Edited by admin on Fri Dec 16 19:50:24 UTC 2022
PRIMARY
EPA CompTox
DTXSID80162594
Created by admin on Fri Dec 16 19:50:24 UTC 2022 , Edited by admin on Fri Dec 16 19:50:24 UTC 2022
PRIMARY
PUBCHEM
5351
Created by admin on Fri Dec 16 19:50:24 UTC 2022 , Edited by admin on Fri Dec 16 19:50:24 UTC 2022
PRIMARY
Related Record Type Details
Structure of SULFOXONE SODIUM
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of SULFOXONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966